Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director | June 16, 2026 | June 17, 2026 |
| MoonLake ImmunotherapeuticsMLTX · Entity 4785 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 181,425 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 63,481 · Balance 181,425 F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
MoonLake Immunotherapeutics
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to BuySEC Table II · derivative / convertible security · Conversion / exercise price $19.19 · Expires 2036-06-17 | Direct | 22,195 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 22,195 · Balance 22,195 F1: This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 22:45 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 22,195 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001213900-26-070256 · ownership.xml · derivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,195 Underlying: Class A ordinary shares, par value $0.0001 per share · 22,195 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 20:36 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 63,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274256 · ownership.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,425 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 20:03 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | Exercise / conversionOption to Buy · Derivative | 23,500 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001213900-25-061752 · ownership.xml · derivative · entry 3 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Class A ordinary shares, par value $0.0001 per share · 23,500 shares Expires 2032-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are fully vested. Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 20:03 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | SaleClass A ordinary shares, par value $0.0001 per share | 23,500 | $48.79 | $1,146,565.00 |
DisclosureSEC source: 0001213900-25-061752 · ownership.xml · nonDerivative · entry 2 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $48.59 to $49.01. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 20:03 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | Exercise / conversionClass A ordinary shares, par value $0.0001 per share | 23,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061752 · ownership.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:27 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085446 · ownership.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,944 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 13:06 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 6,682 | $0.00 Strike: $48.83 | $0.00 |
DisclosureSEC source: 0001213900-25-052366 · ownership.xml · derivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,682 Underlying: Class A ordinary shares, par value $0.0001 per share · 6,682 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 24,311 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076220 · ownership.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,944 F1 · kind: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 20:58 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 35,574 | $6.61 | $235,144.14 |
DisclosureSEC source: 0000950170-24-071393 · ownership.xml · nonDerivative · entry 2 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,633 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.56 to $6.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 21:01 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 7,688 | $0.00 Strike: $42.44 | $0.00 |
DisclosureSEC source: 0001213900-24-050835 · ownership.xml · derivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,688 Underlying: Class A ordinary shares, par value $0.0001 per share · 7,688 shares Expires 2034-06-06 F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:58 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 44,426 | $6.36 | $282,549.36 |
DisclosureSEC source: 0000950170-24-071393 · ownership.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,207 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.43, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059113 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,633 F1 · kind: Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 21:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 2,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049998 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,061 F1 · kind: Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:30 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039142 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,963 F1 · kind: The restricted stock, granted pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038340 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,613 F1 · kind: Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:49 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 11,297 | $0.00 Strike: $29.18 | $0.00 |
DisclosureSEC source: 0001213900-23-048197 · ownership.xml · derivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,297 Underlying: Class A ordinary shares, par value $0.0001 per share · 11,297 shares Expires 2033-06-08 F1 · derivative.exercise_date: This option represents a right to purchase a total of 11,297 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 8, 2024 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019597 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,027 F1 · kind: Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033969 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,350 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| April 06, 2022 Filed May 5, 2022 21:47 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 45,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001213900-22-024303 · ownership.xml · derivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A ordinary shares, par value $0.0001 per share · 45,000 shares Expires 2032-04-06 F1 · derivative.exercise_date: Ms. Moukheibir was granted 45,000 options on April 6, 2022 pursuant to the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (the "Plan"), vesting one-third on each of April 6, 2023, April 6, 2024 and April 6, 2025, in each case, subject to the terms of the Plan. Each option represents the right to acquire one Class A ordinary share, par value $0.0001 per share, of the Issuer. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-019522 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,779 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070230 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,313 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:47 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056657 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,772 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 20:33 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040924 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,325 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038205 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,760 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 1,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021296 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,994 F1 · kind: Issued pursuant to the Director Compensation Policy, effective May 2019. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:36 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034697 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,421 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033633 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,701 F1 · kind: The restricted stock, granted pursuant to the director compensation policy, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:46 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 2,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023463 · doc4.xml · nonDerivative · entry 1 Moukheibir Catherine · CIK 0001772130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,995 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.